[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schizoaffecitve-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schizoaffecitve-disorder":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,84,114,139,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100652930","phase-1-decnef-for-avh-in-schizophrenia-100652930",false,"NCT07779226","DecNef for AVH in Schizophrenia","Decoded fMRI Neurofeedback for Auditory Verbal Hallucinations in Schizophrenia","DecNef","Inclusion Criteria:\n\n* Individuals aged 18 to 55, inclusive at screen\n* Capable of understanding the study procedures and willing and able to provide informed consent\n* Diagnosed with schizophrenia or schizoaffective disorder\n* Taking an antipsychotic medication at a stable dose for at least 4 weeks. All oral and depot antipsychotics are allowable.\n* Mean Auditory Hallucination Rating Scale (AHRS) score \\>2 (moderate) and AHRS Frequency ≥ 4 (hourly AVH: Frequent at least 3 to 6 per hour).\n* Meeting the decoder performance criterion, operationalized as ≥ 55% decoding accuracy. Baseline MRI may be repeated once for subthreshold decoder-accuracy at the discretion of the PIs.\n* Normal hearing, operationalized as normal conversational hearing.\n* Willing to use qualified methods of contraception (listed in section 5.3) for the study duration (for persons of childbearing potential only, unless post-menopausal or surgically sterile).\n\nExclusion Criteria:\n\n* Diagnosis of moderate or severe substance use disorder (excluding nicotine) within the previous 90 days\n* Positive toxicology screen for any substances of abuse\n* Participation in study of investigational medication\u002Fdevice within the past 4 weeks\n* Pregnant persons. Persons of child-bearing potential must have a negative urine β-hCG pregnancy test at Visit 1 and Visit 1a (if applicable)\n* Any clinically significant or unstable medical illness, condition, or disorder that is anticipated to potentially compromise participant safety during study, including history of seizure, epilepsy in self or first degree relatives, stroke, brain surgery, head injury with loss of consciousness \\> 1 hour or clear cognitive sequelae, intracranial metal implants, known structural brain lesions.\n* Contraindication to MRI scanning, including metal implants or clinically meaningful claustrophobia\n* Participants with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the 3 months prior to screening or participants who represent a significant risk of suicide or violence in the opinion of the investigator.\n* History of significant violent behavior in the past 3 months, posing a risk of homicide or having symptoms that would be exacerbated by study participation or travel to the site in the opinion of the investigator.","ALL","18 Years","55 Years",{"count":21,"type":22},51,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The purpose of this study is to learn whether a research neurofeedback training approach done during MRI scans may help reduce hallucinations such as the experience of hearing voices persistent despite treatment.",[29,30],"Schizophrenia Disorder","Schizoaffecitve Disorder",[32,33,34,35,36,37],"Hallucinations","Schizophrenia","Auditory Verbal Hallucinations","Hearing Voices","Schizoaffective","MRI","NOT_YET_RECRUITING","2026-08-19",{"date":41,"type":42},"2026-08-21","ACTUAL",{"date":44,"type":22},"2026-09-01",{"date":46,"type":22},"2028-03-31",{"name":48,"class":49},"New York State Psychiatric Institute","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":50},"100651110","digital-therapeutics-for-social-cognitive-function-in-schizophrenia-spectrum-disorder-a-randomized-controlled-trial-100651110","NCT07755605","Digital Therapeutics for Social Cognitive Function in Schizophrenia Spectrum Disorder","A Prospective, Randomized Parallel, Single Institution, Researcher-led Clinical Trial on the Effect of Improving Social Cognitive Function by Using Digital Therapy Devices in Patients With Schizophrenia Spectrum Disorder","A. Inclusion Criteria\n\nParticipants must meet all of the following criteria:\n\n1. Adults aged 19 to 60 years.\n2. Meet the diagnostic criteria for schizophrenia or schizoaffective disorder according to DSM-5 and ICD-11.\n3. Have completed at least a middle school education.\n4. Be able to read and write in Korean.\n5. Be able to use a smartphone application independently.\n6. Provide written informed consent before participation.\n7. Receiving stable antipsychotic treatment (dose variation ≤30%) for at least 3 months before enrollment.\n\nExclusion Criteria\n\n1. Current or past diagnosis of intellectual disability.\n2. Initiation of or current participation in structured psychosocial interventions (e.g., cognitive behavioral therapy or social cognition training) within the past 3 months.\n3. Considered by the investigator to be at significant risk of suicide. 4, Pregnant or having a positive pregnancy test at screening.\n\n5\\. Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study participation or data interpretation.","19 Years","60 Years",{"count":61,"type":22},60,[63],"NA","The purpose of this study is to evaluate the safety and preliminary effectiveness of a smartphone-based digital therapeutic application (AffectUs) for improving social cognition, particularly emotion processing and social cue perception, in individuals with schizophrenia spectrum disorders.\n\nIn this randomized controlled trial, participants will be assigned either to use AffectUs for 10 weeks in addition to treatment as usual or to receive psychoeducational materials and treatment as usual. Participants will complete assessments at baseline, week 5, week 10, and week 15 to evaluate social cognition, clinical outcomes, and safety.",[33,30],[67,68,69,70,71,72,73,74,75],"Schizophrenia Spectrum Disorder","Social Cognition","Emotion Recognition","Digital Therapeutics","Psychosocial Rehabilitation","AffectUs","Social Cue Perception","Emotion Processing","Mobile Application","RECRUITING",{"date":41,"type":42},{"date":79,"type":42},"2026-07-15",{"date":81,"type":22},"2027-03",{"name":83,"class":49},"Samsung Medical Center",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":91,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100651351","phase-2-combination-therapy-of-deferiprone-and-n-acetylcysteine-for-treating-negative-symptoms-in-schizophrenia-100651351","NCT07759895","Combination Therapy of Deferiprone and N-Acetylcysteine for Treating Negative Symptoms in Schizophrenia","IronMan","Inclusion criteria:\n\n1. Aged 18-55 years.\n2. Diagnosis of schizophrenia\u002Fschizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Disorders- Fifth Edition (DSM-5) criteria. The diagnostic assessment will be conducted using the Structured Clinical Interview for DSM-5 Clinical Trials Version (SCID-5-CT).\n3. Adequate antipsychotic treatment for ≥ 4 months prior to screening (excluding clozapine use).\n4. Stable dose of antipsychotic medication for ≥ 8 weeks prior to screening (excluding clozapine use).\n5. When relevant, stable dose of antidepressants, mood stabilizers and benzodiazepines\u002FZ-drugs for ≥ 8 weeks prior to screening.\n6. Screening and baseline PANSS total score ranging from 60 to 120.\n7. Sum ≥ 20 for the 7 items in the Negative Symptoms subscale of the PANSS.\n8. At least two items in the PANSS Negative Symptoms subscale scored ≥ 4.\n9. Sum \\\u003C 20 for the 7 items in the Positive Symptoms subscale of the PANSS.\n10. Score ≤ 5 for each item in the Positive Symptoms subscale of the PANSS.\n11. Calgary Depression Schizophrenia Scale (CDSS) score of ≤ 6.\n12. Persistent and predominant negative symptoms for ≥ 6 months, in the opinion of the investigator\n13. The subject exhibits clinical stability in both positive and negative symptoms of schizophrenia over the past 6 months, as assessed by the treating psychiatrist and supported by documentation in the medical record.\n14. No incarceration in prison or acute crisis intervention due to symptom exacerbation within 6 months of screening. The subject must be considered psychiatrically stable in the opinion of the investigator.\n15. For males or postmenopausal women, either of the following:\n\n    1. Serum ferritin ≥30 ng\u002FmL at screening. OR\n    2. Serum ferritin 15-29 ng\u002FmL at screening, provided that:\n\n    i. An evaluation of potential underlying causes as well as potentially comorbid deficiencies has been completed, including assessment of folate, vitamin B12, celiac antibodies and H. pylori infection, and, in patients over 40 years old or with positive family history of colorectal cancer, also an appropriate colorectal screening test, alongside other tests deemed as relevant by the investigator; ii. Identified clinically significant causes have been appropriately managed; iii. Repeated ferritin assessment prior to randomization remains within the range of 15-29 ng\u002FmL; and iv. Oral iron supplementation is initiated according to the study protocol.\n16. For premenopausal women: Serum ferritin ≥15 ng\u002FmL at screening.\n17. Screening serum hemoglobin ≥ 13g\u002FdL for males, ≥ 12g\u002FdL for females\n18. Use of contraceptives in women of childbearing age.\n19. Ability to provide informed consent, confirmed by a non-study psychiatrist. When a subject is under guardianship, both patient assent and guardian consent are required. Obtaining written informed consent, dated and signed, is mandatory prior to the initiation of any procedures related to the clinical trial.\n20. Ability to safely undergo MRI scanning, assessed by a non-study psychiatrist.\n21. In the Investigator's opinion, the subject can understand the nature of the trial, comply with study drug administration and protocol procedures or has a guardian able to assist.\n22. Availability of a reliable caregiver or other responsible person (e.g., family member, social worker, nurse) to support treatment adherence and provide collateral information for rating scales.\n\nExclusion criteria:\n\n1. Primary DSM-5 diagnosis other than schizophrenia or schizoaffective disorder in the 12 months prior to screening, according to SCID-5-CT.\n2. Subjects diagnosed with Autistic Spectrum Disorder (ASD).\n3. Subjects diagnosed with Intellectual Developmental Disorder.\n4. Patients who received clozapine within the 6 months preceding the screening.\n5. Patients with a history of relapsing neutropenia (Absolute Neutrophile Count (ANC) \\\u003C 1,500 cells\u002FµL)\n6. Screening ANC ≤ 2,000 cells\u002FµL.\n7. Non-compliance during run-in period (percent adherence ≤ 80%, as examined by pill count).\n8. Improvement \\> 20% in PANSS total score or PANSS negative subscale during the run-in period.\n9. Suicide attempt or serious suicidal behavior within the past 12 months.\n10. Risk for suicidal behavior during the study as determined by the investigator's clinical assessment and Columbia-Suicide Severity Rating Scale (C-SSRS).\n11. The subject has a history of substance use disorder or any illicit drug use (other than nicotine) within the past 3 years.\n12. Positive urine drug screen for drugs of abuse (cocaine, methadone, amphetamines, cannabinoids, opiates, and barbiturates).\n13. Risk of violent behavior in the opinion of the Investigator.\n14. Known hypersensitivity to deferiprone or N-Acetylcysteine.\n15. Pregnancy or intention to become pregnant during the study duration.\n16. Female patients who are lactating.\n17. ECT treatment within 18 weeks prior to screening and study entry.\n18. Patient with substantially confounding extrapyramidal symptoms (according to screening SAS, BARS, AIMS score).\n19. Conditions that are not suitable for partaking in an MRI scan, including metal implants and incompatible devices.\n20. Subjects with BMI ≤ 18 or ≥ 40.\n21. Participation in another clinical trial involving investigational drugs within 3 months prior to screening.\n22. Clinically significant general medical conditions (neurological, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, oncologic) that could interfere with participation.\n23. Major active contagious disease.\n24. Patients with clinically significant abnormalities in hematology, blood chemistry, ECG or physical examination, not resolved by the Baseline visit, that can interfere with study participation.\n25. Any condition that, in the investigator's judgment, may compromise subject safety or interfere with study assessments.",true,"40 Years",{"count":94,"type":22},80,[26],"In following guidelines for studying negative symptoms in schizophrenia, 60 patients aged 18-40, diagnosed with schizophrenia or schizoaffective disorder during the last ten years, will receive a combination of the iron chelator DFP plus NAC or a matching placebo plus NAC combination, as add-on to their maintenance antipsychotic drug (APD) treatment, for a duration of 36 weeks. Prior to initiation of treatment, all participants will undergo baseline MRI scan. A follow-up MRI will be conducted at the end of the 36-week study period, or upon early withdrawal if applicable, to evaluate the effect of the add-on treatment on iron dyshomeostasis and morphology.",[30,98,99],"Schizophrenia and Schizoaffective Disorder","Schizophrenia and Predominant Negative Symptoms",[101,102,33,103,104],"Deferiprone","N-acetylcysteine","Clinical Trial","negative symptoms","2026-08-09",{"date":107,"type":42},"2026-08-12",{"date":44,"type":22},{"date":110,"type":22},"2029-12",{"name":112,"class":49},"Amit Lotan",2,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":50},"100625508","phase-1-a-petmri-study-of-cobenfy-on-dopamine-transmission-in-schizophrenia-100625508","NCT07423546","A PET\u002FMRI Study of Cobenfy on Dopamine Transmission in Schizophrenia","A Multimodal PET\u002FMRI Study of Cobenfy on Dopamine Transmission in Schizophrenia","Inclusion Criteria:\n\n1. Individuals aged 18 to 50, inclusive at screen\n2. Capable of understanding the study procedures and able to provide informed consent\n3. Diagnosed with schizophrenia, schizoaffective, or schizophreniform disorder\n4. Antipsychotic free at Visit 1 (by choice and for reasons unrelated to the study), and for at least 3 weeks (4 for aripiprazole, Cobenfy or LAIs) at the time of the baseline PET scan, inclusive of any antipsychotic-free time prior to consent\n5. PANSS total score \\> 80 and \\\u003C 120\n6. Willing to use qualified methods of contraception (listed in section 5.3) for the study duration (for women of childbearing potential only)\n7. Stable dosing of herbal\u002Fdietary supplements for at least 6 weeks at the time of the first dose of Cobenfy and willingness to avoid products with known hepatotoxic ingredients (e.g., green tea extract, kratom, ashwagandha).\n\nExclusion Criteria:\n\n1. Diagnosis of moderate or severe substance use disorder within the previous month (from first PET scan)\n2. A history of poor or inadequate response to Cobenfy for any reason, hypersensitivity to Cobenfy or trospium or no justifiable reason to expect improvement on Cobenfy, or treatment with Cobenfy within 4 weeks of the first PET Scan\n3. EKG abnormality that is clinically significant including a QT interval \\> 450 msec for men and \\> 470 msec for women, as corrected by the Fridericia formula (QTcF)\n4. Pregnant or breast-feeding women. Women of child-bearing potential must have a negative serum β-hCG pregnancy test at Visit 1, must have been using an acceptable method of contraception (section 5.3) for 30 days before the study, and must agree to do so for the whole study and 30 days after (unless post-menopausal or surgically sterile)\n5. Any clinically significant or unstable medical illness, condition, or disorder that is anticipated to potentially compromise participant safety on study medication, including (but not necessarily limited to) the following: urinary retention, moderate or severe hepatic impairment, gastric retention, untreated narrow-angle glaucoma, hypernasality, resting heart rate \\>100 bpm or systolic Blood Pressure \\>150 mmHg, a history of orthostatic hypotension or abnormal orthostatic blood pressure (change in mean arterial pressure \\[1\u002F3 systolic + 2\u002F3 diastolic\\] of \\> 20% between supine and standing blood pressures), known human immunodeficiency virus (i.e., by history), cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, symptomatic gallstone disease, active hepatic infections, history of bladder stones, recurrent urinary tract infections, or International Prostate Symptom Score \\> 7 or any one item \\> 2 (not including the nocturia item).\n6. Any material in the body that is a contraindication for MRI procedures or participated in prior nuclear medicine procedures in the past year that exceed FDA-defined limits when combined with radiation dosimetry from PET scanning in this protocol to avoid exceeding annual dosimetry limits (metal screener repeated before MRI scan during visit 2)\n7. Participants with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the past 1 month or suicidal behavior in the past 3 months\n8. Laboratory abnormality that would compromise the well-being of the participant, including Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value \\> 2 times the upper limit of the laboratory normal reference range, elevated bilirubin (i.e., \\>2 x upper limit of normal (ULN)), or serum prostate specific antigen (PSA) \\>10 ng\u002Fml (for men only).\n9. A history of treatment resistance to antipsychotics\n10. Use of nicotine products within the previous month (prior to first PET scan)\n11. History of significant violent behavior when antipsychotic-free or currently homicidal\n12. Positive toxicology screen for any substances of abuse","50 Years",{"count":123,"type":22},12,[25,26],"This is a single site clinical trial in which 12 participants with schizophrenia will be randomized to one of three doses of treatment with Cobenfy for 5 weeks. \\[18F\\]DOPA PET scans will be obtained before and after treatment to examine the effects of Cobenfy on dopamine transmission.\n\nThe overall objective of the current study is to measure Cobenfy's ability to engage its putative target (DA transmission\u002Fsynthesis capacity in the striatum and midbrain as measured by \\[18F\\]DOPA Kicer (\\[18F\\]DOPA relative uptake rate)).",[127,30],"SCHIZOPHRENIA 1 (Disorder)",[129,130,37],"Cobenfy","PET","2026-07-10",{"date":133,"type":42},"2026-07-14",{"date":135,"type":42},"2026-07-01",{"date":137,"type":22},"2027-12-31",{"name":48,"class":49},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":23,"phases":148,"briefSummary":149,"conditions":150,"keywords":152,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":164,"locationsCount":113},"100626349","a-virtual-reality-mindfulness-application-for-aggression-in-schizophrenia-100626349","NCT07434479","A Virtual Reality Mindfulness Application for Aggression in Schizophrenia","Inclusion Criteria:\n\nTRIPP MBI VR and TAU Distraction Groups have the same inclusion criteria. Participants will:\n\n1. Is willing and able to provide written informed consent to participate in the study, attend study visits, and comply with study-related requirements and assessments.\n2. Fluent in written and spoken English, confirmed by ability to read and understand the informed consent form.\n3. Be on optimized and stable atypical antipsychotic treatment as indicated by no antipsychotic changes in 2 weeks prior to enrollment.\n4. Demonstrate documented evidence of good medication adherence for the 2 weeks prior to enrollment, as determined by electronic medication records review and prescriber reported adherence to prescribed schedule as documented in the participant's medical records.\n5. Have a history of impulsive aggression as assessed by a score of ≥ 4 on any item on Impulsive Aggression Factor (IA) on the Impulsive- Premeditated Aggression Scale (IPAS; Stanford et al., 2003).\n6. Have adequate visual and auditory abilities to complete assessments, see and hear stimuli in the VR\n7. Has a primary diagnosis of schizophrenia using the diagnostic criteria for schizophrenia or schizoaffective disorder, as defined in the SCID-5-RV at the Screening Visit.\n8. Adult or late adolescent, between 18 and 64 years of age at the time of informed consent.\n\nExclusion Criteria:\n\nParticipants will be excluded if they:\n\n1. Have past head trauma\n2. Diagnosed with a neurological disorder\n3. Are pregnant or breastfeeding women as evidenced by the participant's medical record.\n4. Have unstable medical illness that compromises the safety of the patient\n5. Have significant suicidal ideation at screening (as assessed by the Columbia - Suicide Severity Rating Scale (C-SSRS; participant answers \"Yes\" to \"suicidal ideation\" Item 4 (active suicidal ideation with some intent to act, without a specific plan) or Item 5 (active suicidal ideation with a specific plan and intent) on the C-SSRS; Non-suicidal self-injurious behavior is not exclusionary)\n6. Are on Electroconvulsive therapy (ECT) within 6 months of the study, participants with metal in their bodies or who have claustrophobia or who do not pass the criteria in NKI's Magnetic Resonance Safety Questionnaire (MRSQ)\n7. Score \\\u003C 4 on all items on Impulsive Aggression Factor (IA) on the IPAS (Stanford et al., 2003)\n8. Have a violent episode requiring seclusion, restraints, or a prn within the week before screening\n9. Evidence of suboptimal medication adherence in the 2 weeks prior to enrollment, as determined by electronic medication records review, and demonstrated by prescriber reported non- adherence to prescribed schedule. Suboptimal adherence includes missed doses (two of more missed doses within the past 2 weeks) or plasma levels indicating that the participant is not receiving the intended therapeutic dose.","64 Years",{"count":147,"type":22},58,[63],"The study investigates whether a virtual reality-based mindfulness based intervention can reduce impulsive aggression in individuals with schizophrenia or schizoaffective disorder. The primary goal is to evaluate whether mindfulness delivered via VR (MBI-VR) improves emotion regulation and engages the dorsomedial prefrontal cortex (dmPFC), a brain region involved in cognitive control and regulation of emotional responses. The study also examines whether these effects show a dose-related relationship.\n\nParticipants will be randomized to receive different doses of MBI-VR intervention or distraction tasks and will complete repeated mindfulness VR sessions. Brain activity will be measured using functional magnetic resonance imaging (fMRI) during an emotion regulation task, along with clinical assessments of impulsive aggression related symptoms.",[29,30,151],"Aggression",[153,154,155,156,157],"mindfulness based intervention","schizophrenia","dmPFC","emotion regulation","impulsive aggression","2026-06-09",{"date":160,"type":42},"2026-06-10",{"date":162,"type":22},"2026-06-05",{"date":137,"type":22},{"name":165,"class":49},"Manhattan Psychiatric Center",{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":4},"100639781","phase-2-confirmatory-trial-of-gamma-neurofeedback-to-improve-working-memory-in-schizophrenia-100639781","NCT07592169","Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophrenia","Confirmatory Efficacy Trial to Confirm the Effects of Gamma EEG-Neurofeedback on Working Memory in Schizophrenia","Inclusion Criteria:\n\n* 1\\. DSM-5 diagnosis of schizophrenia or schizoaffective disorder, confirmed by the Structured Clinical Interview for DSM-5 (SCID-5) 2. Age 18-55 years 3. Clinically stable: no psychiatric hospitalization in the 3 months prior to enrollment 4. No change in antipsychotic medication type or dosage within 4 weeks prior to baseline assessment 5. Ascertained to be clinically and medically stable by a study investigator 6. Does not meet DSM-5 diagnostic criteria for bipolar disorder or current major depressive episode 7. No electroconvulsive therapy (ECT) within 6 months of baseline assessment 8. Able to read and speak English (corrected vision or hearing aids acceptable) 9. Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* 1\\. Self-reported history of seizure disorder 2. Diagnosed with multiple sclerosis 3. History of stroke or major vascular disease, including insulin-dependent diabetes mellitus 4. HIV\u002FAIDS diagnosis 5. Current (not past) major depressive episode 6. Substance use disorder other than nicotine use disorder or caffeine use disorder in the past year 7. Brain cancer (primary or metastatic) 8. Prior head injury involving loss of consciousness 9. Inability to read or speak English 10. Color blindness that interferes with administration of study assessments 11. Neuropsychological or cognitive testing in the past 6 months using the same measures as this study 12. Score on Letter-Number Sequencing greater than 1 standard deviation above the age-normed mean",{"count":174,"type":22},104,[26],"This study is a confirmatory, double-blind, placebo-controlled randomized clinical trial (RCT) testing whether gamma EEG neurofeedback (EEG-NFB) improves working memory in adults with schizophrenia or schizoaffective disorder. Participants are randomly assigned to receive either active gamma EEG-NFB (real-time feedback of frontal gamma brain activity) or sham EEG-NFB (false pre-recorded feedback), twice weekly for 12 weeks. Working memory (N-back task), brain gamma coherence, and everyday community functioning are assessed at baseline, mid-treatment, end of treatment, and follow-up.",[127,30],[154,179,180,181,182,183,184,185],"neurofeedback","EEG","gamma oscillations","working memory","randomized controlled trial","n-back","community functioning","2026-05-11",{"date":188,"type":42},"2026-05-18",{"date":190,"type":22},"2026-06-01",{"date":192,"type":22},"2030-05-31",{"name":194,"class":49},"University of California, San Diego"]